drugmaker

Teva Pharm Q4 profit tops estimates, sees mostly flat 2021

Teva Pharm Q4 profit tops estimates, sees mostly flat 2021

  • The world's largest generic drugmaker earned 68 cents per diluted share excluding one-time items in the October-December period, up from 62 cents a share a year earlier.
  • Analysts had forecast Teva would earn 63 cents a share ex-items on revenue of $4.37 billion.
Published 10 Feb, 2021 05:57pm
Europe's top shorted stocks soar on GameStop contagion
World

Europe's top shorted stocks soar on GameStop contagion

  • Evotec surged as much as 30% in Frankfurt at one point as traders rushed into a stock where the US hedge fund headed by Gabriel Plotkin has built a 6.2% short position.
  • Melvin is likely to have lost several million dollars on its bearish bets on GameStop after the US videogame retailer jumped seven-fold since mid January.
Updated 27 Jan, 2021 11:23pm